| 05th week of 2021 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20210030767 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH - The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism. | 2021-02-04 |
| 20210030768 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders - The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) | 2021-02-04 |
| 20210030769 | Composition for Curing Migraine Headaches - The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The compositions are administered to patients having migraines having trigeminal or occipital neuralgia by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves. | 2021-02-04 |
| 20210030770 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS - In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including but not limited to lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes methods of treating one or more clinical neurological conditions with the lithium cholesterol compositions, such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders. | 2021-02-04 |
| 20210030771 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER - Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided. | 2021-02-04 |
| 20210030772 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME - Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease. | 2021-02-04 |
| 20210030773 | PHOSPHATE DERIVATIVES AND USE THEREOF - The present invention discloses a compound with the following formula (I), or a tautomer, mesomer, racemate, enantiomer, and diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug molecule thereof, wherein D is selected from: | 2021-02-04 |
| 20210030774 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR - The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions. | 2021-02-04 |
| 20210030775 | TREATMENT OF HEARING LOSS - Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof. | 2021-02-04 |
| 20210030776 | PARASITICIDAL COMPOSITIONS COMPRISING EPRINOMECTIN AND PRAZIQUANTEL, METHODS AND USES THEREOF - This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising eprinomectin and praziquantel in combination with a pharmaceutically acceptable carrier, and optionally an antioxidant. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 2021-02-04 |
| 20210030777 | TOPICAL FORMUATIONS AND INSTILLATES, KITS, AND METHODS FOR TREATING INTEGUMENTARY WOUNDS, AND USES THEREOF - Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound. | 2021-02-04 |
| 20210030778 | TOPICAL COMPOSITIONS - The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same. | 2021-02-04 |
| 20210030779 | COMBINATION OF A CANNABINOID AND A CHEMOTHERAOPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER - The present invention in the field of cancer therapeutics is based on the finding (illustrated in FIG. | 2021-02-04 |
| 20210030780 | COMPOSITIONS FOR USE TO TREAT CATARACT - A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods. | 2021-02-04 |
| 20210030781 | AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS - It has been discovered that NAD | 2021-02-04 |
| 20210030782 | METHODS FOR REDUCING BIOAVAILABILITY AND ABSORPTION OF INGESTED SUBSTANCES - Methods for reducing at least one of the bioavailability and absorption of at least one of ingested fat, carbohydrates, and unwanted substances from foodstuff in a subject are disclosed. The methods described herein include administering an amount of a nanobiopolymer, or combinations of nanobiopolymers, sufficient to reduce at least one of the bioavailability and absorption of ingested fat, carbohydrates, and unwanted substances to a subject, such as a human subject. | 2021-02-04 |
| 20210030783 | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY - Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy. | 2021-02-04 |
| 20210030784 | Compact gyroplane employing torque compensated main rotor and hybrid power train. - A compact, compound gyroplane employing torque compensated main rotor and hybrid power train is disclosed. The invention incorporates a torque-compensated main rotor system with a common Collective pitch control but no Cyclic function, which can be driven transiently during flight to allow vertical take-off, landing and hovering flight operations; torque compensation is via a coaxial counter-rotating (CACR) rotor system, or alternatively using one or more electronically-controlled, fixed-pitch, thruster motors. A mechanical or electro-mechanical hybrid power system allows a single engine to power vertical lift and forward propulsion; the use of electric motors for lift and torque compensation facilitates electronic (and potentially autonomous) control of critical phases of flight. | 2021-02-04 |
| 20210030785 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION - Provided herein are methods for preventing transmission of Zika virus, and of preventing diseases, disorders and symptoms associated with Zika virus infections, in particular for preventing transmission during sexual intercourse. The methods comprise topical administration of a macromolecule comprising a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the dendrimer. Also provided herein are related uses, compositions, devices and systems. | 2021-02-04 |
| 20210030786 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE - The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate. | 2021-02-04 |
| 20210030787 | METHODS FOR PROTECTING HAIR FOLLICLES - Disclosed herein are compositions including a topical agent that may be used to reduce and/or inhibit the effects of chemotherapy and/or radiotherapy, which can include reducing and/or inhibiting the effects of hair loss and/or hair shedding due to chemotherapy and/or radiotherapy. The topical agent can be hydrogen sulfide, a hydrogen sulfide donor, or a substrate for a hydrogen sulfide producing enzyme such as sulfanegen. Some embodiments of the composition can include the topical agent combined with an agent to promote vasoconstriction or the topical agent combined with an agent to modulate deposition, mode of action, and/or metabolism of a chemotherapeutic agent and/or a reactive oxygen species agent. Embodiments can be used for improving the outcome of a hair transplant surgery by optimizing a holding solution to stabilize hair follicle grafts. In yet another embodiment, a system for realizing hydrogen sulfide slowly into a holding solution is described. | 2021-02-04 |
| 20210030788 | PREVENTIVE AND CURATIVE PEROXOMETALLATE BASED COMPOSITION, NOTABLY PHARMACEUTICAL COMPOSITION - The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (V), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory. | 2021-02-04 |
| 20210030789 | COMPOSITIONS AND METHODS FOR NEUROPROTECTION UTILIZING NANOPARTICULATE SILVER - A preparation of silver nanoparticles has been found to be effective in improving functional and behavioral recovery from traumatic spinal cord injury. The silver nanoparticles are provided in a non-flowable gel vehicle, from which they are release at high efficiency, that is applied locally at the site of the spinal cord injury. Silver nanoparticle formulations described herein were found to modify the M1/M2 macrophage phenotype ratio and provides a synergistic effect in the combination with arginase to promote healing processes at the treated injury site, reducing postinjury inflammation. | 2021-02-04 |
| 20210030790 | METHODS AND TREATMENT OF TRAUMA - Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. | 2021-02-04 |
| 20210030791 | Methods and Uses For Dendritic Cell Therapy - This invention provides methods of evaluating immune system parameters to identify and treat patients who are likely to experience more favorable treatment outcomes. This invention also provides methods for treating a human patient with a dendritic cell therapy by obtaining at least one value or measurement of the level and/or amount of a particular type of treatment indicator in the patient, confirming that said value or measurement exceeds or is less than the treatment threshold value for that value or measurement, and administering said dendritic cell therapy to the patient. | 2021-02-04 |
| 20210030792 | Composition for Promoting Increase in Subcutaneous Tissue and Subcutaneous Adipose Tissue - In particular, a composition for breast augmentation that includes a composition promoting an increase in subcutaneous tissue, wherein the promoting composition aims at accumulating and increasing adipose tissue under the skin of a breast by generating and increasing the adipose tissue around a mammary gland and enables recovery of autologous tissue and recovery of appearance by a safe and natural process, and a method for breast augmentation are provided. A composition promoting an increase in subcutaneous tissue that contains autologous plasma and a basic fibroblast growth factor (b-FGF), in particular, a composition for breast augmentation is provided. A composition for breast augmentation that includes the above-described composition promoting an increase in subcutaneous tissue that further contains fat is provided. Specifically, a composition for breast augmentation that includes the above-described composition promoting an increase in subcutaneous tissue, wherein the fat is in the form of a lipid emulsion and the lipid emulsion is an oil-in-water lipid emulsion produced by emulsifying fat and oil in the presence of an emulsifier, and a method for breast augmentation by using the composition are provided. An injection unit of the composition for breast augmentation is also provided. | 2021-02-04 |
| 20210030793 | METHODS AND COMPOSITIONS FOR TREATING CD33+ CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS - The application relates to a chimeric receptor that targets CD33 and allows activation of the co-stimulatory pathway without binding the natural ligand. The application also relates to polynucleotides that encode the chimeric receptor, vectors, and host cells comprising the chimeric receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo persistence of the chimeric antigen receptor host cells. | 2021-02-04 |
| 20210030794 | GAMMA DELTA T CELLS AND USES THEREOF - A method of preparing and using gamma delta T cells in the allogeneic or autologous treatment of subjects suffering from virus infection, fungal infection, protozoal infection and cancer. | 2021-02-04 |
| 20210030795 | ALLOGENEIC T-CELL-BASED HIV VACCINE TO INDUCE CELLULAR AND HUMORAL IMMUNITY - Provided herein are methods for treating a patient with human immunodeficiency virus (HIV), comprising administering cellular compositions comprising recombinant allogeneic cells, such as CD4+ T cells. The present invention further relates to compositions and methods for making an allogeneic T-cell-based protective HIV vaccine that induces both cellular and humoral immunity. Related compositions and methods for modulating the immune system using such recombinant cells are also provided. | 2021-02-04 |
| 20210030796 | METHOD FOR PRODUCING ANTIGEN-SPECIFIC T CELLS - The present invention relates to a method for producing antigen-specific T cells, the antigen-specific T cells produced by the method, and a pharmaceutical composition containing the antigen-specific T cells. | 2021-02-04 |
| 20210030797 | METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration. | 2021-02-04 |
| 20210030798 | CHIMERIC RECEPTOR - The present invention provides a chimeric receptor which binds a target antigen on a target cell, which comprises: a first antigen binding domain which binds a first epitope of the target antigen, a second antigen binding domain which binds a second epitope of the target antigen; a transmembrane domain; and an intracellular signalling domain. | 2021-02-04 |
| 20210030799 | TUMOR ENVIRONMENT-SPECIFIC EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS - A Tumor Micro-Environment (TME) responsive expression vector including a nucleic acid sequence encoding a synthetic promoter comprising one or more promoter-response-elements, and a nucleic acid sequence encoding immune-effector genes, such as chimeric antigen receptor. The TME responsive vector is designed to induce the expression of immune-effector genes within TME, and not in normal healthy tissues, thus focusing immune activities, increasing safety and reducing the ON-target OFF-tumor hazard. | 2021-02-04 |
| 20210030800 | ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING - Antigen binding fragments, chimeric antigen receptors, and bi-specific T-cell engagers having specificity for MICA and methods for using the same in the diagnosis and treatment of disorders associated with MICA and/or MICB expression are provided. | 2021-02-04 |
| 20210030801 | METHOD FOR PREPARING CHIMERIC ANTIGEN RECEPTOR (CAR)-CARRYING EXOSOMES DERIVED FROM IMMUNE CELLS, AND USE OF CAR-CARRYING EXOSOMES - Provided are a method for preparing chimeric antigen receptor (CAR)-carrying exosomes derived from immune cells through isolation, and use of the CAR-carrying exosomes. The method includes: A) preparation of CAR expressing immune cells; B) antigen-specific activation of the CAR expressing immune cells; C) isolation of exosomes secreted by CAR expressing immune cells; and D) purification and enrichment of CAR exosomes. The immune cells in step A are T cells or NK cells; and the immune cells are derived from a patient or a healthy donor. CAR expressing immune cells are activated with specific antigens, and the resulting exosomes are further analyzed, isolated, purified and enriched to finally obtain CAR-carrying exosomes derived from immune cells. The exosomes can be used for treating cancer, severe infectious diseases, and other diseases. | 2021-02-04 |
| 20210030802 | GLUCOCORTICOID-RESISTANT LEUKOCYTES AND THEIR USE IN THE TREATMENT OF CANCERS AND VIRUSES - A composition including genetically modified leukocytes is provided, where the genetically modified leukocytes contains a gene or expresses a protein that confers reversible resistance to glucocorticoids. In various aspects, the gene that confers resistance to glucocorticoids encodes 11-beta-dehydrogenase. Administering such genetically modified leukocytes provides leukocyte functions in treating one or more auto-immune, inflammatory, infectious or cancerous diseases or disorders, where the leukocytes are resistant to the effects of glucocorticoids such as alterations of numerous gene transcriptions in the leukocytes. Methods of reversing the glucocorticoid resistance in such genetically modified leukocytes are also provided by administering inhibitors of 11-beta-hydroxysteroid dehydrogenase. Methods of modifying the growth of these genetically modified leukocytes, or identification of candidate inhibitors of glucocorticoid resistance based on these genetically modified leukocytes, are also provided. | 2021-02-04 |
| 20210030803 | METHODS FOR MANUFACTURING T CELLS - The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells. | 2021-02-04 |
| 20210030804 | CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS - The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level. | 2021-02-04 |
| 20210030805 | CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2021-02-04 |
| 20210030806 | INTRAPERITONEAL INJECTION OF HUMAN PLACENTA STEM CELLS PROTECT THE BRAIN FROM STROKE INJURY VIA EXOSOME/MICROPARTICLE FORMATION AND ACE2 MAINTENANCE OF BRAIN PERFUSION - Therapeutics and methods of treating a stroke in a patient comprising delivering stem cells into a peritoneum of the patent. According to a further embodiment the stem cells are mesenchymal stem cells. According to a further embodiment the stem cells are human placenta mesenchymal stem cells (hPMSC). According to a further embodiment the stroke is one of stroke is one of occlusive, post-occlusive, hemorrhagic, and transient ischemic injury. According to a further embodiment the method further comprises the step of delivering a clot busting compound into a blood stream of the patient. | 2021-02-04 |
| 20210030807 | CELL-TYPE SPECIFIC EXOSOMES AND USE THEREOF - Provided herein are highly-characterized isolated exosomes, methods to produce such exosomes, and methods for the use of such exosomes in treating diseases such as neurodegenerative diseases. | 2021-02-04 |
| 20210030808 | CULTURE SCAFFOLD FOR PROMOTING STEM CELL DIFFERENTIATION COMPRISING MULTILAYER GRAPHENE FILM - Provided are a culture scaffold for promoting stem cell differentiation comprising a multilayer graphene film, a method of regulating growth and differentiation of a stem cell using the culture scaffold, and a method of preparing the culture scaffold, where the culture scaffold is capable of promoting the osteogenic differentiation of stem cells as a result of laminating a graphene film without comprising an additional substance, and it may be variously applicable to application fields of stem cells in/outside the body. | 2021-02-04 |
| 20210030809 | CELLULAR COMPOSITIONS DERIVED FROM PRIOR ORGAN DONORS AND METHODS OF MANUFACTURE AND USE THEREOF - The invention provides methods of making and using compositions for establishing mixed chimerism in a subject that include CD34 | 2021-02-04 |
| 20210030810 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL CORD INJURY - The present invention provides methods for treating spinal cord injury (SCI). Such methods involve administering E40RF1+ endothelial cells and neural cells (such as neural progenitor cells (NPCs), glial progenitor cells, or glial cells) to subjects having a SCI. The present invention also provides compositions useful in such methods, such as compositions comprising E40RF1+ endothelial cells and/or neural cells (such as NPCs, glial progenitor cells, or glial cells). | 2021-02-04 |
| 20210030811 | USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS - Various aspects described herein provide methods of generating alveolar or alveolar/airway organoids from a population of lung cells to differentiate into alveolar or alveolar/airway organoids. Also provided herein are methods and compositions for treating lung disease comprising transplantation of the alveolar or alveolar/airway organoids, or a cell isolated therefrom to a subject. | 2021-02-04 |
| 20210030812 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS - The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH. | 2021-02-04 |
| 20210030813 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF - Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin | 2021-02-04 |
| 20210030814 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INTESTINAL PARACELLULAR PERMEABILITY - The present invention provides methods and compositions for maintaining and improving the integrity of gastrointestinal epithelial tight junctions, thereby helping to maintain healthy paracellular permeability of the GI epithelium. The present invention provides methods and compositions for the treatment or prevention of various conditions that are associated with gastrointestinal paracellular permeability, including various autoimmune conditions, inflammatory liver diseases, as well as inflammatory conditions of the large or small intestines. | 2021-02-04 |
| 20210030815 | METHOD FOR SELECTING PROBIOTICS - Provided is an improved method for selecting a probiotic microorganism composition, the method comprising providing a first consortium of microorganisms having Microorganism Composition A; providing a first host animal having a first microbiome having Microorganism Composition B; administering said first consortium to said first host animal, whereby said first microbiome is converted to a second microbiome having Microorganism Composition C; collecting a first sample of said second microbiome; and transferring at least a fraction of said first sample and/or said treated first sample onto and/or into a growth medium and incubating at a temperature between 15 degrees Celsius and 70 degrees Celsius to form first selected microorganism composition having Microorganism Composition D; wherein Microorganism Composition A of said first consortium comprises at least 50 different strains; wherein each of Compositions A and B; B and C and D and A differ from each other. | 2021-02-04 |
| 20210030816 | FEED INGREDIENT COMPRISING CLOSTRIDIUM TYROBUTYRICUM - Provided is a feed ingredient comprising at least 20% by weight | 2021-02-04 |
| 20210030817 | METHODS FOR MAKING AND USING ANTIMICROBIAL PEPTIDES - Provided herein are genetically modified microbes. In one embodiment, a genetically modified microbe includes an exogenous polynucleotide that includes a pheromone-responsive region. In one embodiment, the pheromone-responsive region is derived from a conjugative plasmid from a member of the genus | 2021-02-04 |
| 20210030818 | COMPOSITIONS FOR USE IN BALANCING MICROBIOME - The disclosure generally provides a method of balancing microbiome and/or improving nutrient absorption, treating gut inflammation, and/or balancing the level of Firmicutes and Bacteroidetes in the gut of a subject in need thereof, the method comprising consumption by, or administration to the subject of a composition comprising a nutrient in combination with a probiotic composition comprising (i) an isolated non-pathogenic fungal strain and (ii) an isolated non-pathogenic bacterial strain. | 2021-02-04 |
| 20210030819 | EDIBLE PLANT PARTS ENRICHED WITH PROBIOTIC BACTERIA - The present invention relates to edible plant parts or tissues comprising probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue. | 2021-02-04 |
| 20210030820 | COMPOSITION COMPRISING NEW LACTOBACILLUS SALIVARIUS STRAINS AND METHOD FOR THE PREVENTION AND TREATMENT OF OTITIS AND UPPER RESPIRATORY INFECTIONS - A strain of | 2021-02-04 |
| 20210030821 | NANOVESICLES DERIVED FROM LACTOBACILLUS SP. BACTERIA, AND USE THEREOF - Provided are vesicles derived from bacteria of the genus | 2021-02-04 |
| 20210030822 | PROBIOTIC PATHOGEN INHIBITION COMPOSITION AND METHOD - A bacterial composition and method that inhibits | 2021-02-04 |
| 20210030823 | NOVEL ADENO-ASSOCIATED VIRUS VIRION FOR TREATMENT OF TAY-SACHS DISEASE AND SANDHOFF DISEASE - According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified β-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the β-subunit of wild-type human β-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid. | 2021-02-04 |
| 20210030824 | MODULAR, INTEGRATED PROCESS AND APPARATUS FOR EXTRACTING, REFINING AND REMEDIATING ACTIVE SUBSTANCES FROM PLANT MATERIAL - The present disclosure relates to scalable processes for extracting, refining and remediating extracts of natural products, such as plant material and for providing well controlled refined extract. | 2021-02-04 |
| 20210030825 | USE OF CRASSOCEPHALUM RABENS EXTRACT IN THE TREATMENT OF BREAST CANCER - A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment including administering to said subject an effective amount of | 2021-02-04 |
| 20210030826 | COSMETIC COMPOSITIONS - Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from | 2021-02-04 |
| 20210030827 | TREATMENT OF DERMATOLOGICAL CONDITIONS - The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries. | 2021-02-04 |
| 20210030828 | COMPOSITION FOR PREVENTING OR TREATING DRY EYE SYNDROME, CONTAINING AUCUBA JAPONICA EXTRACT - Provided is a composition for preventing, alleviating or treating dry eye syndrome, containing an | 2021-02-04 |
| 20210030829 | METHODS FOR TREATMENT OF CANCER AND ENHANCEMENT OF NANOPARTICLE ACCUMULATION IN TISSUES - Provided are methods for treating tumors and/or cancers. In some embodiments, the methods relate to administering to a subject in need thereof an effective amount of a nanoparticle derived from an edible plant and an effective amount of an autologous exosome. Also provided are methods for enhancing accumulation of nanoparticles in the lungs of subjects, methods for delivering agents to the liver, brain, and/or bones of subjects, and methods for delivering agents across the blood-brain barrier of subjects. | 2021-02-04 |
| 20210030830 | COMPOSITION FOR IMPROVING QUANTITY OF TEAR FLUID, COMPOSITION FOR IMPROVING CONSTIPATION, AND COMPOSITION FOR IMPROVING SKIN QUALITY - The present invention relates to a composition for improving the quantity of tear fluid, a composition for improving constipation, and a composition for improving skin quality. By containing the extract of Black ginger ( | 2021-02-04 |
| 20210030831 | COMPOSITION AND METHOD FOR IMPROVING QUANTITY OF TEAR FLUID, COMPOSITION, TREATING CONSTIPATION AND IMPROVING SKIN QUALITY - The present invention relates to a composition and method for improving the quantity of tear fluid, a composition and method for treating constipation, and a composition and method for improving skin quality. By utilizing an extract of Black ginger ( | 2021-02-04 |
| 20210030832 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE - The present application provides bifunctional compounds of Formula X or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK. | 2021-02-04 |
| 20210030833 | OPHTHALMIC PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The invention relates to an ophthalmic pharmaceutical composition and its preparation methods and applications, wherein the pharmaceutical composition comprises of L-Alanyl-L-Glutamine suspended or dissolved in an isoosmotic solution suitable for human eyes, and has the advantages causing minimal irritation, with high stability and a good safety profile, and which can be used for relieving dry eye disease (DED) symptoms and/or improving and/or treating DED. | 2021-02-04 |
| 20210030834 | METHODS FOR ADMINISTERING ANGIOTENSIN II - The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension. | 2021-02-04 |
| 20210030835 | PEPTIDE-CONTAINING FORMULATIONS - A formulation comprising glutamic acid, or a salt thereof, and an effective amount of a peptide is provided. The invention also provides a method of preparing the formulation, methods of treating a condition using the formulation, and a kit containing components of the formulation. The invention further provides a sustained release formulation for drug substances comprising glutamic acid, or a salt thereof, and an amount of a peptide. | 2021-02-04 |
| 20210030836 | Novel Tumor Microenvironment-Related Target TAK1 and Application Thereof in Inhibition of Tumor - Disclosed are a novel tumor microenvironment-related target TAK1 and an application thereof in inhibition of a tumor. TAK1, as a research target for SASP regulation, can be used as a marker in tumor diagnosis and prognosis, and can also be used as a tumor microenvironment specific target to develop tumor inhibitory drugs. | 2021-02-04 |
| 20210030837 | ANGIOGENESIS INHIBITOR AND SCREENING METHOD FOR ANGIOGENESIS INHIBITORS - The present invention provides an angiogenesis inhibitor containing as an active ingredient LYPD1 protein or a derivative thereof, a part thereof, or a vector expressing the same, or a cell expressing the same. The present invention also provides a screening method for angiogenesis inhibitors that enhance the expression of LYPD1 protein wherein the method includes (i) a step for treating a first cell by a test substance and culturing and (ii) a step for detecting the expression level of LYPD1 protein from the first cell and comparing with the level of LYPD1 protein of an untreated first cell. | 2021-02-04 |
| 20210030838 | CHEMOTAXIS-POTENTIATING PEPTIDES AND USES THEREOF - The present invention relates to peptides which are capable of potentiating the chemotactic potential of glycosaminoglycan binding chemokines, and to the use of said chemotaxis-potentiating peptides in the treatment of cancer. | 2021-02-04 |
| 20210030839 | SWEET TASTE RECEPTOR ANTAGONIST COMPOSITIONS - The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject. | 2021-02-04 |
| 20210030840 | Methods and Compositions for Improving Quality of Life and Increasing Activity in Aging and Chronically Ill Mammals - Methods for improving quality of life and/or increasing activity in an aging and/or chronically ill mammal via administration of a composition of egg yolk powder are provided. In some embodiments, additional agents improving quality of life and/or increasing activity in an aging and/or chronically ill mammal are administered in combination with the egg yolk powder. | 2021-02-04 |
| 20210030841 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF - The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss. | 2021-02-04 |
| 20210030842 | FOCAL TREATMENT OF PROSTATE CANCER - The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated. | 2021-02-04 |
| 20210030843 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT - Plinabulin and one or more G-CSF drugs are used for treating a chemotherapy induced neutropenia, stimulating neutrophil survival, reducing bone pain induced by the G-CSF drug and alleviating immune suppression effect induced by the G-CSF drug. For example, docetaxel-induced neutropenia can be reduced by-co-administering plinabulin and one or more G-CSF compounds. | 2021-02-04 |
| 20210030844 | IL-15-BASED MOLECULES AND METHODS OF USE THEREOF - The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases. | 2021-02-04 |
| 20210030845 | VASOINTESTINAL PEPTIDE RECEPTOR INHIBITORS FOR ENHANCEMENT OF GASTROINTESTINAL HEALTH - Provided are compositions and methods for maintaining intestinal immune homeostasis. The method comprises administering to an individual an effective amount of a VIPR2 inhibitor. The method may modulate gut resident CCR6 | 2021-02-04 |
| 20210030846 | LONG-ACTING FATTY ACID-CONJUGATED GnRH DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - An aspect of the present disclosure pertains to a novel long-acting fatty acid-conjugated gonadotrophin-releasing hormone (GnRH) derivative and a pharmaceutical composition containing the same. A GnRH derivative of the present invention is expected to greatly contribute, through excellent bioavailability, increased half-life in blood, and remarkably high therapeutic effects on sex hormone-dependent disease, to the reduction in drug dosing frequency and dosage and the like in the treatment of sex hormone-dependent diseases. Particularly, the GnRH derivative can overcome the disadvantages of existing GnRH sustained-release preparations, which have the side effects of residual feeling and pain at the injection site. | 2021-02-04 |
| 20210030847 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON - Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon can be used to treat or prevent post-bariatric hypoglycemia. | 2021-02-04 |
| 20210030848 | ELEVATED INTRACRANIAL PRESSURE TREATMENT - Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis. | 2021-02-04 |
| 20210030849 | LIQUID COMPOSITION FOR ORAL USE CONTAINING COLLAGEN PEPTIDE, AND METHOD FOR IMPROVING FLAVOR OF LIQUID COMPOSITION FOR ORAL USE INCLUDING COLLAGEN PEPTIDE - The present invention provides a technique to reduce the unpleasant odor, particularly medium-like odor, and bitterness of a liquid oral composition containing low molecular weight collagen peptides. The present invention relates to a liquid oral composition containing collagen peptides having an average molecular weight of 300 to 2000 and welan gum. | 2021-02-04 |
| 20210030850 | EXTRACELLULAR VESICLES COMPRISING TARGETING AFFINITY DOMAIN-BASED MEMBRANE PROTEINS - Disclosed are extracellular vesicles comprising an engineered targeting protein for targeting the extracellular vesicles to target cells. The targeting protein is a fusion protein that includes (i) an affinity agent, such as a single-chain variable fragment of an antibody (scFv), which is expressed on the surface of the extracellular vesicles and (ii) a transmembrane domain, and may include additional domains. Exemplary extracellular vesicles may include but are not limited to exosomes or microvesicles. | 2021-02-04 |
| 20210030851 | COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - Provided herein are compositions and methods for enhancing expression of SMN protein in a cell. In one embodiment, the composition comprises a site-specific nuclease targeting the ISS-N1 region of human SMN2 gene. Also provided are compositions and methods for treating or ameliorating spinal muscular atrophy. | 2021-02-04 |
| 20210030852 | METHODS OF TREATMENT FOR CANDIDA AURIS INFECTIONS - Disclosed herein are compositions and methods for treating and immunizing against | 2021-02-04 |
| 20210030853 | TICK VACCINE - The present invention relates to combinations of tick-derived antigens for use as a tick vaccine. | 2021-02-04 |
| 20210030854 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-02-04 |
| 20210030855 | METHODS AND COMPOSITIONS FOR TREATING CANCERS - The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation. | 2021-02-04 |
| 20210030856 | CANCER IMMUNIZATION PLATFORM - The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD | 2021-02-04 |
| 20210030857 | BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use. | 2021-02-04 |
| 20210030858 | METHODS AND MATERIALS FOR TREATING CANCER - This document relates to methods and materials for treating a mammal having cancer. For example, compositions (e.g., vaccines) containing cells (e.g., tumor cells) expressing APOBEC3 which can be administered to a mammal (e.g., a human) having cancer to induce an immune response (e.g., an anti-tumor immune response) within the mammal are provided. | 2021-02-04 |
| 20210030859 | USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORS - This invention relates to compositions (e.g. vaccine compositions) which can be used to provide a subject with protective immunity against a parasite infection. The compositions comprise: (i) an immunologically effective amount of a nucleic acid (e.g. a nucleic acid-based vaccine) comprising a sequence which encodes a parasite macrophage migration inhibitory factor (MIF) antigen; (ii) a parasite MIF antigen; or (iii) an antibody which specifically binds to a parasite MIF antigen. The compositions may be used to treat infections and diseases caused by parasitic protozoans, such as a | 2021-02-04 |
| 20210030860 | SELF-ANTIGEN SPECIFIC T-CELLS AS VACINES FOR AUGMENTING ENGRAFTMENT AND STABILITY OF AUTOLOGOUS TRANSFER - Disclosed are compositions and methods relating to genetically modified cells for the long-term expression of an antigen of interest. | 2021-02-04 |
| 20210030861 | KLEBSIELLA PNEUMONIAE FROM MINKS AND ITS APPLICATION - A SD-1 strain of | 2021-02-04 |
| 20210030862 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS - The present invention pertains to a vaccine comprising an IgM protease antigen of | 2021-02-04 |
| 20210030863 | IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS - The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by | 2021-02-04 |
| 20210030864 | BUNYAVIRALES VACCINE - The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines. | 2021-02-04 |
| 20210030865 | METHOD FOR DETERMINING VACCINE EFFICACY IN AN INDIVIDUAL AND MEANS THEREFORE - In a first aspect, the present invention relates to a method for determining the responsiveness of an individual to vaccination, like viral vaccination or for the determination of viral vaccine efficacy in an individual as well as a method for the stratification of the vaccination regimen, e.g. viral vaccination, in an individual based on determining the level or the amount of at least one of IL-8 or IL-18 in a sample; said sample is obtained from an individual at least once before or at least once after vaccination. The method allows to determine the vaccination regimen with the vaccine, in particular, a virus vaccine, like an influenza virus vaccine whereby when a low level of at least one of IL-8 and/or IL-18 is determined, said low level is indicative for a personalized vaccine strategy. In a further aspect, the use of at least one of IL-8 or IL-18 as a predictive marker for vaccine efficacy or immune protection by vaccination is provided. Finally, a kit of parts for vaccination comprising equipment for determining the level and/or amount of at least one of IL-8 or IL-18 in a sample obtained from an individual to be vaccinated as well as the vaccine to be administered is described. | 2021-02-04 |
| 20210030866 | VACCINATION IN NEWBORNS AND INFANTS - The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit. | 2021-02-04 |
